These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32745178)

  • 21. The role of microRNAs in melanoma.
    Luo C; Weber CE; Osen W; Bosserhoff AK; Eichmüller SB
    Eur J Cell Biol; 2014; 93(1-2):11-22. PubMed ID: 24602414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The promise of microarray technology in melanoma care.
    Kim CJ; Reintgen DS; Yeatman TJ
    Cancer Control; 2002; 9(1):49-53. PubMed ID: 11907466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melanocytes and melanoma: hooked on elongation.
    Lister JA
    Pigment Cell Melanoma Res; 2011 Jun; 24(3):397-8. PubMed ID: 22489316
    [No Abstract]   [Full Text] [Related]  

  • 24. Review and cross-validation of gene expression signatures and melanoma prognosis.
    Schramm SJ; Campain AE; Scolyer RA; Yang YH; Mann GJ
    J Invest Dermatol; 2012 Feb; 132(2):274-83. PubMed ID: 21956122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing Genetic Expression Profiles in Melanoma Diagnosis.
    Leachman SA; Mengden Koon S; Korcheva VB; White KP
    Dermatol Clin; 2017 Oct; 35(4):537-544. PubMed ID: 28886810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Melanoma progression, gene expression and DNA microarrays.
    Hoek KS
    G Ital Dermatol Venereol; 2009 Feb; 144(1):39-49. PubMed ID: 19218910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor biomarkers in melanoma.
    Ugurel S; Utikal J; Becker JC
    Cancer Control; 2009 Jul; 16(3):219-24. PubMed ID: 19556961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting clinical outcome through molecular profiling in stage III melanoma.
    John T; Black MA; Toro TT; Leader D; Gedye CA; Davis ID; Guilford PJ; Cebon JS
    Clin Cancer Res; 2008 Aug; 14(16):5173-80. PubMed ID: 18698035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of gene expression profile testing as a prognostic tool in early-stage cutaneous melanoma - compelling but not ready for primetime.
    Christensen L; Scott J; Bordeaux J
    Melanoma Res; 2018 Dec; 28(6):652-654. PubMed ID: 30211811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of Genetic Aberrations in the Assessment and Prognosis of Melanoma.
    High WA
    Dermatol Clin; 2017 Oct; 35(4):525-536. PubMed ID: 28886809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of tissue microarray for the immunohistochemical profiling of melanoma.
    Pacifico MD; Grover R; Richman P; Daley F; Wilson GD
    Melanoma Res; 2004 Feb; 14(1):39-42. PubMed ID: 15091192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma.
    Amaral TMS; Hoffmann MC; Sinnberg T; Niessner H; Sülberg H; Eigentler TK; Garbe C
    Eur J Cancer; 2020 Jan; 125():38-45. PubMed ID: 31838403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of new molecular tests for melanoma by pigmented-lesion experts.
    Varedi A; Gardner LJ; Kim CC; Chu EY; Ming ME; Leachman SA; Curiel-Lewandrowski C; Swetter SM; Grossman D
    J Am Acad Dermatol; 2020 Jan; 82(1):245-247. PubMed ID: 31415835
    [No Abstract]   [Full Text] [Related]  

  • 34. A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis.
    Zhao Y; Schaafsma E; Gorlov IP; Hernando E; Thomas NE; Shen R; Turk MJ; Berwick M; Amos CI; Cheng C
    Mol Cancer Res; 2019 Jan; 17(1):109-119. PubMed ID: 30171176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic tissue markers in melanoma.
    Moore DA; Pringle JH; Saldanha GS
    Histopathology; 2012 Apr; 60(5):679-89. PubMed ID: 21880059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
    J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of long noncoding RNA and messenger RNA signatures in melanoma tumorigenesis and metastasis.
    Wang S; Fan W; Wan B; Tu M; Jin F; Liu F; Xu H; Han P
    PLoS One; 2017; 12(2):e0172498. PubMed ID: 28225791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-sequencing data analyzing melanoma development and progression.
    Linck L; Liebig J; Völler D; Eichner N; Lehmann G; Meister G; Bosserhoff A
    Exp Mol Pathol; 2018 Dec; 105(3):371-379. PubMed ID: 30414979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
    Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
    BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Melanoma Gene Expression Markers for Surveillance of Epidermolysis Bullosa Nevi Malignant Transformation.
    Ahn JW; Johnson K; Kohen LL; Chaffins ML; Shwayder T
    JAMA Dermatol; 2016 May; 152(5):584-6. PubMed ID: 26865206
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.